In May 2022, FDA granted accelerated approval to Kymriah, tisagenlecleucel, developed by Novartis Pharmaceuticals Corporation, for adult patients with relapsed or refractory FL (Follicular Lymphoma) post at least two lines of systemic therapy.
▶️ 𝐀𝐜𝐜𝐞𝐬𝐬 𝐅𝐮𝐥𝐥 𝐒𝐮𝐦𝐦𝐚𝐫𝐲: - https://www.marknteladvisors.c....om/research-library/
#non_hodgkin_lymphoma_market #lymphoma #immunotherapy #therapy #pharmaceuticals #bloodcancer #marketresearch #marknteladvisors #healthcare
Like
Comment
Share
1 (877) 773-1002